Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Autosomal recessive intermediate Charcot-Marie-Tooth disease type B is an extremely rare subtype of autosomal recessive intermediate Charcot-Marie-Tooth (CMT) disease characterized by a CMT neuropathy associated with developmental delay, self-abusive behavior, dysmorphic features and vestibular Schwannoma. Motor nerve conduction velocities demonstrate features of both demyelinating and axonal pathology.
Features include always present findings: Decreased compound muscle action potential amplitude, Global developmental delay, Vestibular schwannoma, and Self-injurious behavior. 10 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 4 | Hyporeflexia, Steppage gait, Global developmental delay |
Muscles | 2 | Decreased compound muscle action potential amplitude, Foot dorsiflexor weakness |
Ears | 1 | Vestibular schwannoma |
Arms and legs | 1 | Foot dorsiflexor weakness |
KARS1 encodes lysyl-tRNA synthetase 1 (597 aa). Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA. Highest expression in Cells EBV-transformed lymphocytes (185.3 TPM) and Cells Cultured fibroblasts (142.7 TPM).
Charcot-Marie-Tooth disease recessive intermediate B is associated with mutations in the KARS1 gene on chromosome 16.
KARS1 is classified as a druggable target (Druggable Genome and Enzyme categories) with score 0.0.
Genetic testing for KARS1 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 4 always present features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Charcot-Marie-Tooth disease recessive intermediate B.
3 publications have been identified in PubMed for Charcot-Marie-Tooth disease recessive intermediate B. Research spans Review / Meta-Analysis (33%), Basic Science / Preclinical (33%), and Gene Therapy / Novel Therapeutics (33%).
Estévez-Arias B (2025). [PMID: 40814755](https://pubmed.ncbi.nlm.nih.gov/40814755/). *Ann Neurol*. [Gene Therapy / Novel Therapeutics]
Zhang H (2025). [PMID: 39487674](https://pubmed.ncbi.nlm.nih.gov/39487674/). *IUBMB Life*. [Review / Meta-Analysis]
Cashman CR (2025). [PMID: 40400204](https://pubmed.ncbi.nlm.nih.gov/40400204/). *Ann Clin Transl Neurol*. [Basic Science / Preclinical]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 3:00 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Charcot-Marie-Tooth disease recessive intermediate B